CADL 6.15 Candel Therapeutics, Inc.
| Range: | 0.66-14.3 | Vol Avg: | 258310 | Last Div: | 0 | Changes: | 0.19 |
| Beta: | -0.94 | Cap: | 0.19B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Tue Jul 27 2021 | Empoloyees: | 42 | ||
| CUSIP: | 137404109 | CIK: | 0001841387 | ISIN: | US1374041093 | Country: | US |
| CEO: | Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. | Website: | https://www.candeltx.com | ||||
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow